(Q35954719)

English

Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

11 August 2017

Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus (English)

1 reference

Europe PubMed Central

11 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

systemic lupus erythematosus

1 reference

based on heuristic

inferred from title

10

object named as

Douglas R Hough

1 reference

Europe PubMed Central

11 August 2017

2

object named as

Falk Hiepe

1 reference

Europe PubMed Central

11 August 2017

7

object named as

Cynthia Aranow

1 reference

Europe PubMed Central

11 August 2017

author name string

William Stohl

1

1 reference

Europe PubMed Central

11 August 2017

Kevin M Latinis

3

1 reference

Europe PubMed Central

11 August 2017

Mathew Thomas

4

1 reference

Europe PubMed Central

11 August 2017

Morton A Scheinberg

5

1 reference

Europe PubMed Central

11 August 2017

Ann Clarke

6

1 reference

Europe PubMed Central

11 August 2017

Frank R Wellborne

8

1 reference

Europe PubMed Central

11 August 2017

Carlos Abud-Mendoza

9

1 reference

Europe PubMed Central

11 August 2017

Lilia Pineda

11

1 reference

Europe PubMed Central

11 August 2017

Thi-Sau Migone

12

1 reference

Europe PubMed Central

11 August 2017

Z John Zhong

13

1 reference

Europe PubMed Central

11 August 2017

William W Freimuth

14

1 reference

Europe PubMed Central

11 August 2017

W Winn Chatham

15

1 reference

Europe PubMed Central

11 August 2017

BLISS-52 Study Group

16

1 reference

Europe PubMed Central

11 August 2017

BLISS-76 Study Group

17

1 reference

Europe PubMed Central

11 August 2017

publication date

1 July 2012

1 reference

Europe PubMed Central

11 August 2017

Arthritis & Rheumatology

1 reference

Europe PubMed Central

11 August 2017

64

1 reference

Europe PubMed Central

11 August 2017

7

1 reference

Europe PubMed Central

11 August 2017

2328-2337

1 reference

Europe PubMed Central

11 August 2017

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3350827

2 October 2017

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3350827

2 October 2017

Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3350827

2 October 2017

Novel evidence-based systemic lupus erythematosus responder index

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3350827

2 October 2017

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3350827

2 October 2017

The socioeconomic burden of SLE.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3350827

2 October 2017

Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3350827

2 October 2017

SLE--a disease of clearance deficiency?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3350827

2 October 2017

TACI and BAFF-R mediate isotype switching in B cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3350827

2 October 2017

Generation and characterization of LymphoStat‐B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3350827

2 October 2017

DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3350827

2 October 2017

Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3350827

2 October 2017

Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3350827

2 October 2017

Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3350827

2 October 2017

BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3350827

2 October 2017

TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3350827

2 October 2017

Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3350827

2 October 2017

Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3350827

2 October 2017

BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3350827

2 October 2017

BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3350827

2 October 2017

Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3350827

2 October 2017

Prevalence of flare and influence of demographic and serologic factors on flare risk in systemic lupus erythematosus: a prospective study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3350827

11 July 2018

Immunologic factors and clinical activity in systemic lupus erythematosus.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3350827

11 July 2018

Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3350827

24 September 2018

Systemic lupus erythematosus.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3350827

24 September 2018

BAFF enhances chemotaxis of primary human B cells: a particular synergy between BAFF and CXCL13 on memory B cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3350827

24 September 2018

Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3350827

24 September 2018

BAFF mediates survival of peripheral immature B lymphocytes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3350827

24 September 2018

Combined oral contraceptives in women with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1002%2FART.34400

21 January 2018

From BILAG to BLIPS--disease activity assessment in lupus past, present and future

1 reference

https://api.crossref.org/works/10.1002%2FART.34400

21 January 2018

BAFF is a survival and maturation factor for mouse B cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/22275291

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Development of Autoantibodies before the Clinical Onset of Systemic Lupus Erythematosus

1 reference

https://pubmed.ncbi.nlm.nih.gov/22275291

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The anti-apoptotic factor Bcl-2 can functionally substitute for the B cell survival but not for the marginal zone B cell differentiation activity of BAFF

1 reference

https://pubmed.ncbi.nlm.nih.gov/22275291

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP)

1 reference

https://pubmed.ncbi.nlm.nih.gov/22275291

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects

1 reference

https://pubmed.ncbi.nlm.nih.gov/22275291

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/22275291

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/ART.34400

1 reference

Europe PubMed Central

11 August 2017

1 reference

Europe PubMed Central

11 August 2017

1 reference

Europe PubMed Central

11 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35954719&oldid=1618035641"